Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Daiichi Sankyo
US Army
McKesson
Fuji
Cantor Fitzgerald
UBS
Express Scripts

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,350,756

« Back to Dashboard

Title: Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
Abstract:This invention discloses a method for increasing the effectiveness of dextromethorphan (DM) as an antitussive agent (i.e., as a cough suppressant). This method involves the concurrent administration of DM and a second agent which inhibits the oxidative activity of debrisoquin hydroxylase, a cytochrome P450 oxidase enzyme. Effective anti-oxidant compounds include quinidine, yohimbine, and fluoxetine.
Inventor(s): Smith; Richard A. (La Jolla, CA)
Assignee:
Filing Date:May 28, 1992
Application Number:07/890,432
Claims:1. A method of treating a patient to suppress severe coughing which cannot be suppressed adequately by dextromethorphan alone, comprising administering to a patient in need thereof a combination of dextromethorphan, and a pharmaceutically acceptable second compound which inhibits enzymatic oxidation of dextromethorphan by debrisoquin hydroxylase, wherein the second compound is selected from the group consisting of quinidine, quinine, and salts and isomers thereof.

2. The method of claim 1 wherein quinidine is administered to a patient at a dosage not exceeding about 150 milligrams per day.

3. A method of treating a patient to suppress coughing, comprising administering to a patient who is an extensive metabolizer of dextromethorphan and who is in need of cough suppression a combination of dextromethorphan and a second compound which, in the body of that patient, is pharmaceutically acceptable and causes a significant inhibition of enzymatic oxidation of dextromethorphan by debrisoquin hydroxylase, wherein the second compound is selected from the group consisting of quinidine, quinine, and salts and isomers thereof.

4. The method of claim 3 wherein quinidine is administered to a patient at a dosage not exceeding about 150 milligrams per day.

5. In the method of using dextromethorphan as a cough suppressant, the improvement wherein a patient who is receiving dextromethorphan as a cough suppressant and who is an extensive metabolizer of dextromethorphan also receives a second compound which, in the body of that patient, is pharmaceutically acceptable and causes a significant inhibition of oxidation of dextromethorphan by debrisoquin hydroxylase, and wherein the second compound is selected from the group consisting of quinidine, quinine, and salts and isomers thereof.

6. The method of claim 5 wherein quinidine is administered to a patient at a dosage not exceeding about 150 milligrams per day.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
Cipla
Express Scripts
Healthtrust
Federal Trade Commission
Farmers Insurance
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.